文献速递前列腺癌

前列腺癌根治性放疗患者中雄激素剥夺治疗与急性肾损伤的关系

Androgen deprivation therapy and acute kidney injury in patients with prostate cancer undergoing definitive radiotherapy.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-11-22

该研究基于美国退伍军人数据库分析27868例接受根治性放疗的前列腺癌患者,其中754例单独放疗、9114例联合ADT。诊断后2年急性肾损伤发生率在联合组为10.5%,单独放疗组为7.9%(Gray检验p<0.01)。多因素分析显示ADT与任何急性肾损伤风险升高相关(SHR=1.24,95%CI=1.14-1.36,p<0.01),并与轻度及中度急性肾损伤风险升高相关,但与重度急性肾损伤无显著关联。

要点

  • 接受根治性放疗的前列腺癌患者中,ADT使用与急性肾损伤风险升高相关(SHR=1.24)。
  • 诊断后2年急性肾损伤发生率:RT+ADT组10.5% vs RT组7.9%(p<0.01)。
  • ADT与轻度和中度急性肾损伤风险升高相关,但与重度急性肾损伤无显著关联。

核心结论

  • 研究证实,在接受根治性放疗的前列腺癌患者中,使用ADT与急性肾损伤风险升高相关。
  • 临床医生应警惕该人群发生肾功能不全的可能性。

研究设计与样本

  • 回顾性队列研究,纳入2001年至2015年间接受根治性放疗±ADT的前列腺癌退伍军人27868例,使用退伍军人事务部信息与计算基础设施(VINCI)进行分析。
  • 暴露定义为诊断后一年内使用ADT;主要结局为急性肾损伤,定义为血清肌酐升至基线值的至少1.5倍,并按国际指南分为轻度、中度或重度。
  • 采用多因素竞争风险模型校正人口学、肿瘤学因素以及已知影响急性肾损伤风险的药物和操作。

主要发现

  • 多数患者(n=18754)仅接受放疗,9114例接受放疗+ADT。
  • 诊断后2年急性肾损伤发生率:RT+ADT组10.5% vs RT组7.9%(Gray检验p<0.01)。
  • 多因素分析显示,ADT使用与任何急性肾损伤风险升高相关(SHR=1.24,95%CI=1.14-1.36,p<0.01)。
  • ADT与轻度急性肾损伤风险升高相关(SHR=1.13,95%CI=1.01-1.27,p=0.04)。
  • ADT与中度急性肾损伤风险升高相关(SHR=1.45,95%CI=1.20-1.76,p<0.01),但与重度急性肾损伤无显著关联(SHR=1.33,95%CI=0.93-1.91,p=0.11)。

临床怎么用

  • 临床医生应警惕接受根治性放疗的前列腺癌患者使用ADT时发生肾功能不全的可能性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen deprivation therapy (ADT) is frequently utilized in conjunction with radiotherapy (RT) in the definitive management of prostate cancer. Prior studies have suggested an association between ADT use and acute kidney injury (AKI), however, these included heterogeneous populations undergoing a variety of treatments and relied on billing codes to ascertain the incidence of AKI. METHODS: We analyzed a cohort of 27,868 veterans undergoing definitive RT + /- ADT for prostate cancer between 2001 and 2015 using the Veterans Affairs Informatics and Computing Infrastructure (VINCI). Exposure was defined as use of ADT within one year of diagnosis. The primary outcome was AKI, defined by an increase in serum creatinine to at least 1.5 times the baseline value. AKIs were classified as mild, moderate, or severe in accordance with international guidelines. A multivariate competing risks model was used to account for demographic and oncologic factors as well as medications and procedures known to influence the risk of AKI. RESULTS: Most (n = 18,754) men received RT alone; 9,114 men received RT + ADT. The incidence of AKI at two years after diagnosis was 10.5% in the RT + ADT group and 7.9% in the RT group (Gray's test p < 0.01). Multivariate analysis confirmed ADT usage was associated with an increased risk for any AKI (SHR = 1.24, 95% CI = 1.14-1.36, p < 0.01). ADT was also associated with an increased risk of mild AKI (SHR = 1.13, 95% CI = 1.01-1.27, p = 0.04) and moderate AKI (SHR = 1.45, 95% CI = 1.20-1.76, p < 0.01), though not severe AKI (SHR = 1.33, 95% CI = 0.93-1.91, p = 0.11). CONCLUSIONS: Our findings confirm that use of ADT is associated with an increased risk of AKI in patients undergoing definitive RT for prostate cancer. Clinicians should be alert to the potential for renal dysfunction in this population.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sherer MV, Deka R, Salans MA, et al. Androgen deprivation therapy and acute kidney injury in patients with prostate cancer undergoing definitive radiotherapy. Prostate Cancer Prostatic Dis. 2021. PMID: 34811501. doi:10.1038/s41391-021-00415-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。